Neurological manifestations of immune origin after COVID-19 vaccination: retrospective case study

被引:0
作者
Lopez, Juan Granja [1 ,2 ]
Armas, Carlos Estebas [1 ,2 ]
Dieguez, Manuel Lorenzo [1 ,2 ]
Munoz, Inmaculada Puertas [1 ,2 ]
Ruiz, Elena De Celis [1 ,2 ]
Rigual, Ricardo [1 ,2 ]
Fernandez-Fournier, Mireya [1 ,2 ]
Iglesias, Gabriel Torres [1 ,2 ]
Velasco, Sara Sanchez [1 ,2 ]
Barranco, Antonio Tallon [1 ,2 ]
Rogozina, Olga [3 ]
Ramirez, Elena [3 ]
Gonzalez-Munoz, Miguel [4 ]
Ballester, Laura Lacruz [1 ,2 ]
机构
[1] Univ Autonoma Madrid, Inst Hlth Res Inst IdiPAZ, Lab Neurol & Cerebrovasc Sci, Neurol Dept,La Paz Univ Hosp,Hosp La Paz, Madrid, Spain
[2] Univ Autonoma Madrid, Inst Hlth Res Inst IdiPAZ, Lab Neurol & Cerebrovasc Sci, Stroke Ctr,La Paz Univ Hosp,Hosp La Paz, Madrid, Spain
[3] Univ Autonoma Madrid, La Paz Univ Hosp IdiPAZ, Fac Med, Clin Pharmacol Dept, Madrid, Spain
[4] La Paz Univ Hosp IdiPAZ, Immunol Dept, Madrid, Spain
关键词
COVID-19; vaccination; autoimmune disorders; polyradiculoneuropathy; cranial neuropathy; Spanish pharmacovigilance system causality algorithm; lymphocyte transformation test; CAUSALITY ASSESSMENT; VACCINES; COMPLICATIONS;
D O I
10.3389/fphar.2024.1376474
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: To know the frequency and characteristics of neurological manifestations of probable immune origin occurring after exposure to COVID-19 vaccination. In addition, to pre-study the usefulness of the Spanish pharmacovigilance system and lymphocyte transformation test in establishing causality.Methods: Retrospective case study, including patients admitted to the Neurology department from January 2021 to May 2022 with a probable neuroimmune disorder. Demographic, clinical and COVID-19 vaccination antecedent data were collected from medical records.Results: From a total of 108 patients, 30 were excluded due to a different etiological diagnosis after follow-up. Thirty-six patients (46.2%) had received the COVID-19 vaccine in the previous 3 months (21.8% during the previous month). BioNTech-Pfizer vaccine was the most frequent in this group (63.9%). 69/108 were female and mean age 51.2 years (SD 22.59), with no significant difference with not recently-vaccinated (U-Mann Whitney, p = 0.256). The neurological syndromes found were (vaccinated/total): polyradiculoneuropathy (8/16), encephalitis (5/11), multiple sclerosis relapse (5/16), optic neuritis (1/4), myelitis (3/6), cranial neuropathy (6/10), aseptic meningitis (1/3) and others (7/11). Acute immunosuppressive treatment was administered in 61.1% of cases and 47.2% presented complete clinical improvement, without significant differences with non-vaccinated patients (chi-square, p = 0.570). Eleven vaccinated patients were studied in the pharmacovigilance office for possible adverse drug reaction. Causality according to the Spanish pharmacovigilance system (SPVS) algorithm was "Related" to COVID-19 vaccine (score >= 4) in 11 cases with positive in vitro study (lymphocyte transformation test) to polyethylene glycol-2000 and polysorbate-80 in 4 cases.Conclusion: Neuroimmune disorders appearing after administration of COVID-19 vaccine do not seem to present important differentiating clinical and/or evolutive features. Delayed hypersensitivity to vaccine excipients could be one of the pathophysiological mechanisms, and lymphocyte transformation test is a useful tool to identify it.
引用
收藏
页数:10
相关论文
共 34 条
  • [1] aemps, 2024, 19o Informe de Farmacovigilancia sobre Vacunas COVID-19 | Agencia Espanola de Medicamentos y Productos Sanitarios
  • [2] Safety of COVID-19 vaccines
    Aga, Qutaiba A. Al Khames
    Alkhaffaf, Waseem H.
    Hatem, Tagreed H.
    Nassir, Kawthar F.
    Batineh, Yazan
    Dahham, Abdullah T.
    Shaban, Dimah
    Aga, Luma A. Al Khames
    Agha, Manhal Y. R.
    Traqchi, Muaamar
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (12) : 6588 - 6594
  • [3] Causality assessment in reports on adverse drug reactions. Algorithm of Spanish pharmacovigilance system
    Aguirre, Carmelo
    Garcia, Montserrat
    [J]. MEDICINA CLINICA, 2016, 147 (10): : 461 - 464
  • [4] Alonso Castillo R, 2022, Neurologia (Engl Ed), DOI 10.1016/j.nrleng.2022.09.007
  • [5] mRNA COVID-19 Vaccination Does Not Exacerbate Symptoms or Trigger Neural Antibody Responses in Multiple Sclerosis
    Blanco, Yolanda
    Escudero, Domingo
    Lleixa, Cinta
    Llufriu, Sara
    Egri, Natalia
    Garcia, Raquel Ruiz
    Alba, Mercedes
    Aguilar, Esther
    Artola, Montse
    Aldea Novo, Marta
    Alvarez, Silvia
    Caballero, Eva
    Cabrera-Maqueda, Jose Maria
    Fonseca, Elianet
    Guasp, Mar
    Hernando, Ana
    Martinez-Hernandez, Eugenia
    Olive-Cirera, Gemma
    Lopez-Contreras, Joaquin
    Martin-Aguilar, Lorena
    Martinez-Martinez, Laura
    Rombauts, Alexander
    Rodes, Maria
    Sabater, Lidia
    Sepulveda, Maria
    Solana, Elisabeth
    Tejada-Illa, Clara
    Vidal-Fernandez, Nuria
    Vilella, Anna
    Fortuny, Claudia
    Armangue, Thais
    Dalmau, Josep O.
    Querol, Luis
    Saiz, Albert
    [J]. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2023, 10 (06):
  • [6] brightoncollaboration, 2023, Case definitions.
  • [7] Considerations for causality assessment of neurological and neuropsychiatric complications of SARS-CoV-2 vaccines: from cerebral venous sinus thrombosis to functional neurological disorder
    Butler, Matt
    Tamborska, Arina
    Wood, Greta K.
    Ellul, Mark
    Thomas, Rhys H.
    Galea, Ian
    Pett, Sarah
    Singh, Bhagteshwar
    Solomon, Tom
    Pollak, Thomas Arthur
    Michael, Benedict D.
    Nicholson, Timothy R.
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2021, 92 (11) : 1144 - 1151
  • [8] Allergy to COVID-19 vaccines: A current update
    Cabanillas, Beatriz
    Novak, Natalija
    [J]. ALLERGOLOGY INTERNATIONAL, 2021, 70 (03) : 313 - 318
  • [9] Neurological complications of coronavirus and COVID-19
    Carod-Artal, Francisco J.
    [J]. REVISTA DE NEUROLOGIA, 2020, 70 (09) : 311 - 322
  • [10] Neurological Complications Following COVID-19 Vaccination
    Chatterjee, Aparajita
    Chakravarty, Ambar
    [J]. CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2023, 23 (01) : 1 - 14